Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy

Rasmus K Petersen, Søren Hess, Abass Alavi, Poul F Høilund-Carlsen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

FDG-PET/CT is rarely used for initial staging of patients with colorectal cancer (CRC). Surgical resection of primary tumor and isolated metastases may result in long-term survival or presumed cure, whereas disseminated disease contraindicates operation. We analyzed a retrospective material to elucidate the potential value of FDG-PET/CT for staging of CRC. Data were retrieved from 67 consecutive patients (24-84 years) with histopathologically proven CRC who had undergone FDG-PET/CT in addition to conventional imaging for initial staging. Treatment plans before and after FDG-PET/CT were compared and patients divided as follows: (A) Patients with a change in therapy following FDG-PET/CT and (B) Patients without a change following FDG-PET/CT. Sixty-two patients had colon and five had rectal cancer. Of these, 20 (30%; CI 20.2-41.7) belonged to group A, whereas 47 (70%; CI 58.3-79.8) fell in group B. In conclusion, FDG-PET/CT changed treatment plan in 30% of cases. In ⅓ of these there was either a change from intended curative to palliative therapy or vice versa, while in the remaining ⅔ the pattern was more mixed. Thus, even in a retrospective routine material there were substantial changes in management strategy following FDG-PET/CT for staging in CRC.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Nuclear Medicine and Molecular Imaging
Vol/bind4
Udgave nummer5
Sider (fra-til)471-82
ISSN2160-8407
StatusUdgivet - 2014

Fingeraftryk

Neoplasm Staging
Colorectal Neoplasms
Rectal Neoplasms
Palliative Care
Colon
Neoplasms

Citer dette

@article{63585b294c7e435f963f9d875fb1db72,
title = "Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy",
abstract = "FDG-PET/CT is rarely used for initial staging of patients with colorectal cancer (CRC). Surgical resection of primary tumor and isolated metastases may result in long-term survival or presumed cure, whereas disseminated disease contraindicates operation. We analyzed a retrospective material to elucidate the potential value of FDG-PET/CT for staging of CRC. Data were retrieved from 67 consecutive patients (24-84 years) with histopathologically proven CRC who had undergone FDG-PET/CT in addition to conventional imaging for initial staging. Treatment plans before and after FDG-PET/CT were compared and patients divided as follows: (A) Patients with a change in therapy following FDG-PET/CT and (B) Patients without a change following FDG-PET/CT. Sixty-two patients had colon and five had rectal cancer. Of these, 20 (30{\%}; CI 20.2-41.7) belonged to group A, whereas 47 (70{\%}; CI 58.3-79.8) fell in group B. In conclusion, FDG-PET/CT changed treatment plan in 30{\%} of cases. In ⅓ of these there was either a change from intended curative to palliative therapy or vice versa, while in the remaining ⅔ the pattern was more mixed. Thus, even in a retrospective routine material there were substantial changes in management strategy following FDG-PET/CT for staging in CRC.",
author = "Petersen, {Rasmus K} and S{\o}ren Hess and Abass Alavi and H{\o}ilund-Carlsen, {Poul F}",
year = "2014",
language = "English",
volume = "4",
pages = "471--82",
journal = "American Journal of Nuclear Medicine and Molecular Imaging",
issn = "2160-8407",
publisher = "E-Century Publishing Corporation",
number = "5",

}

Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. / Petersen, Rasmus K; Hess, Søren; Alavi, Abass; Høilund-Carlsen, Poul F.

I: American Journal of Nuclear Medicine and Molecular Imaging, Bind 4, Nr. 5, 2014, s. 471-82.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy

AU - Petersen, Rasmus K

AU - Hess, Søren

AU - Alavi, Abass

AU - Høilund-Carlsen, Poul F

PY - 2014

Y1 - 2014

N2 - FDG-PET/CT is rarely used for initial staging of patients with colorectal cancer (CRC). Surgical resection of primary tumor and isolated metastases may result in long-term survival or presumed cure, whereas disseminated disease contraindicates operation. We analyzed a retrospective material to elucidate the potential value of FDG-PET/CT for staging of CRC. Data were retrieved from 67 consecutive patients (24-84 years) with histopathologically proven CRC who had undergone FDG-PET/CT in addition to conventional imaging for initial staging. Treatment plans before and after FDG-PET/CT were compared and patients divided as follows: (A) Patients with a change in therapy following FDG-PET/CT and (B) Patients without a change following FDG-PET/CT. Sixty-two patients had colon and five had rectal cancer. Of these, 20 (30%; CI 20.2-41.7) belonged to group A, whereas 47 (70%; CI 58.3-79.8) fell in group B. In conclusion, FDG-PET/CT changed treatment plan in 30% of cases. In ⅓ of these there was either a change from intended curative to palliative therapy or vice versa, while in the remaining ⅔ the pattern was more mixed. Thus, even in a retrospective routine material there were substantial changes in management strategy following FDG-PET/CT for staging in CRC.

AB - FDG-PET/CT is rarely used for initial staging of patients with colorectal cancer (CRC). Surgical resection of primary tumor and isolated metastases may result in long-term survival or presumed cure, whereas disseminated disease contraindicates operation. We analyzed a retrospective material to elucidate the potential value of FDG-PET/CT for staging of CRC. Data were retrieved from 67 consecutive patients (24-84 years) with histopathologically proven CRC who had undergone FDG-PET/CT in addition to conventional imaging for initial staging. Treatment plans before and after FDG-PET/CT were compared and patients divided as follows: (A) Patients with a change in therapy following FDG-PET/CT and (B) Patients without a change following FDG-PET/CT. Sixty-two patients had colon and five had rectal cancer. Of these, 20 (30%; CI 20.2-41.7) belonged to group A, whereas 47 (70%; CI 58.3-79.8) fell in group B. In conclusion, FDG-PET/CT changed treatment plan in 30% of cases. In ⅓ of these there was either a change from intended curative to palliative therapy or vice versa, while in the remaining ⅔ the pattern was more mixed. Thus, even in a retrospective routine material there were substantial changes in management strategy following FDG-PET/CT for staging in CRC.

M3 - Journal article

VL - 4

SP - 471

EP - 482

JO - American Journal of Nuclear Medicine and Molecular Imaging

JF - American Journal of Nuclear Medicine and Molecular Imaging

SN - 2160-8407

IS - 5

ER -